InsiderTrades.com logo
Natarajan Sethuraman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Natarajan Sethuraman Biography and Net Worth

Insider of Entrada Therapeutics

Natarajan is President of Research and Development at Entrada Therapeutics and is responsible for research, and the clinical development and operations of the company’s intracellular therapeutics pipeline that is aimed at multiple neuromuscular, ocular, metabolic and immune mediated diseases, among others. Natarajan joined Entrada as Chief Scientific Officer in 2017 with deep and broad experience in drug discovery and development with different modalities including oligonucleotides, antibodies, therapeutic enzymes, and peptides at start-up biotech and large-scale biopharma. He was promoted to President of Research and Development in 2024.

Prior to Entrada, Natarajan was at Merck & Co., Inc. for 10 years leading the GlycoFi site and the research and development of novel biologics. He joined Merck in 2006 with the acquisition of GlycoFi. Prior to that, Natarajan was Senior Scientist at Medical Enzymes for 11 years where he led the end-to-end development of drug candidates aimed at cancer and viral diseases.

Natarajan holds a PhD in Entomology, Molecular Biology and Biochemistry from the Indian Agricultural Research Institute, a BSc from Tamil Nadu Agricultural University and completed his post-doctoral training at Duke University.

What is Natarajan Sethuraman's net worth?

The estimated net worth of Natarajan Sethuraman is at least $1.66 million as of November 11th, 2024. Sethuraman owns 163,588 shares of Entrada Therapeutics stock worth more than $1,662,054 as of December 4th. This net worth estimate does not reflect any other investments that Sethuraman may own. Additionally, Sethuraman receives an annual salary of $694,300.00 as Insider at Entrada Therapeutics. Learn More about Natarajan Sethuraman's net worth.

How old is Natarajan Sethuraman?

Sethuraman is currently 62 years old. There are 3 older executives and no younger executives at Entrada Therapeutics. Learn More on Natarajan Sethuraman's age.

What is Natarajan Sethuraman's salary?

As the Insider of Entrada Therapeutics, Inc., Sethuraman earns $694,300.00 per year. The highest earning executive at Entrada Therapeutics is Mr. Dipal Doshi, CEO & Director, who commands a salary of $968,210.00 per year. Learn More on Natarajan Sethuraman's salary.

How do I contact Natarajan Sethuraman?

The corporate mailing address for Sethuraman and other Entrada Therapeutics executives is , , . Entrada Therapeutics can also be reached via phone at 857-520-9158 and via email at [email protected]. Learn More on Natarajan Sethuraman's contact information.

Has Natarajan Sethuraman been buying or selling shares of Entrada Therapeutics?

Natarajan Sethuraman has not been actively trading shares of Entrada Therapeutics during the last quarter. Most recently, Natarajan Sethuraman sold 2,700 shares of the business's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $20.04, for a transaction totalling $54,108.00. Following the completion of the sale, the insider now directly owns 160,888 shares of the company's stock, valued at $3,224,195.52. Learn More on Natarajan Sethuraman's trading history.

Who are Entrada Therapeutics' active insiders?

Entrada Therapeutics' insider roster includes John Crowley (Director), Dipal Doshi (CEO), Nathan Dowden (President and Chief Operating Officer), Kush Parmar (Director), Natarajan Sethuraman (Insider), and Kory Wentworth (CFO). Learn More on Entrada Therapeutics' active insiders.

Are insiders buying or selling shares of Entrada Therapeutics?

In the last twelve months, Entrada Therapeutics insiders bought shares 3 times. They purchased a total of 178,044 shares worth more than $1,352,567.90. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 685,845 shares worth more than $5,867,281.75. The most recent insider tranaction occured on November, 21st when CFO Kory James Wentworth sold 8,910 shares worth more than $88,921.80. Insiders at Entrada Therapeutics own 8.1% of the company. Learn More about insider trades at Entrada Therapeutics.

Information on this page was last updated on 11/21/2025.

Natarajan Sethuraman Insider Trading History at Entrada Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2024Sell2,700$20.04$54,108.00160,888View SEC Filing Icon  
11/11/2024Sell1,409$20.01$28,194.09163,588View SEC Filing Icon  
10/16/2024Sell600$18.00$10,800.00183,216View SEC Filing Icon  
9/9/2024Sell2,642$15.09$39,867.78183,816View SEC Filing Icon  
9/6/2024Sell600$15.24$9,144.00186,458View SEC Filing Icon  
7/15/2024Sell638$18.00$11,484.00188,814View SEC Filing Icon  
7/12/2024Sell600$18.00$10,800.00189,452View SEC Filing Icon  
5/20/2024Sell9,675$15.19$146,963.25190,052View SEC Filing Icon  
5/16/2024Sell1,000$15.00$15,000.00208,032View SEC Filing Icon  
7/10/2023Sell3,026$18.00$54,468.00168,299View SEC Filing Icon  
4/17/2023Sell3,961$18.00$71,298.00171,325View SEC Filing Icon  
See Full Table

Natarajan Sethuraman Buying and Selling Activity at Entrada Therapeutics

This chart shows Natarajan Sethuraman's buying and selling at Entrada Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Entrada Therapeutics Company Overview

Entrada Therapeutics logo
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $10.16
Low: $9.52
High: $10.38

50 Day Range

MA: $7.48
Low: $5.80
High: $10.26

2 Week Range

Now: $10.16
Low: $4.93
High: $21.79

Volume

123,914 shs

Average Volume

286,123 shs

Market Capitalization

$388.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A